Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Benitec Biopharma Ltd ADR (BNTC)

Benitec Biopharma Ltd ADR (BNTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Benitec Biopharma Ltd ADR 3940 Trust Way Hayward CA 94545 USA

www.benitec.com P: 510-780-0819

Description:

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.

Key Statistics

Overview:

Market Capitalization, $K 12,729
Enterprise Value, $K 10,239
Shares Outstanding, K 2,592
Annual Sales, $ 80 K
Annual Net Income, $ -19,560 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -5,950 K
EBIT, $ -20,370 K
EBITDA, $ -20,230 K
60-Month Beta 1.03
% of Insider Shareholders 4.30%
% of Institutional Shareholders 52.19%
Float, K 2,481
% Float 95.70%
Short Volume Ratio 0.26

Growth:

1-Year Return 31.70%
3-Year Return -94.98%
5-Year Return -99.00%
5-Year Revenue Growth -97.81%
5-Year Earnings Growth 93.56%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.64 on 02/13/24
Latest Earnings Date 05/20/24
Earnings Per Share ttm -8.88
EPS Growth vs. Prev Qtr 4.35%
EPS Growth vs. Prev Year 22.35%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-17 on 07/26/23

BNTC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -204.34%
Return-on-Assets % -142.81%
Profit Margin % -24,450.00%
Debt/Equity 0.00
Price/Sales 190.11
Price/Cash Flow N/A
Price/Book 0.91
Book Value/Share 8.75
Interest Coverage -651.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar